Neoplasms

All Conditions

Symptoms and General Pathology

Rare Diseases

Sarcoma

Neoplasm Metastasis

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antoine Italiano, MD/PhD

Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals.

The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group will be analyzed with a focus on : number/frequency of systemic treatments per patient, number/frequency of patients with locoregional treatment of the metastasis, number/frequency of patients with chemotherapy, number/frequency of patients with an off-label drug.

Outcome (time-to-next treatment \[TNT\] and overall survival \[OS\]) will be reported according to histological subtype, as well as the association between TNT and OS.

Prognostic factors of OS will be investigated.

METASARC: Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa

Patterns of Care and Outcomes of Patients With METAstatic Soft Tissue SARComa in a Real-life Setting: the METASARC Observational Study

TNT: time from the systemic treatment onset to the next treatment or death due to any cause, whichever came first.

OS: time from the systemic treatment onset to death

French Sarcoma Group

Institut Bergonié

Patients with metastatic softtissue sarcomas diagnosed between 1990 and 2013 satisfying all eligibility criteria

Patients With Metastatic Softtissue Sarcomas Diagnosed Between 1990 and 2013

Patients with metastatic softtissue sarcomas diagnosed between 1990 and 2013 and satisfying all eligibility criteria

Age, Customized

Sex: Female, Male

France

Region of Enrollment

Pr Antoine Italiano

Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment

Overall Study

All Drugs and Chemicals

Immunomodulating Agents

Immunologic Factors

Chemotherapy

Immunotherapeutic Agent

target treatment

Surgery

Radiotherapy

Maud Toulmonde, MD

Simone Mathoulin-Pélissier, MD/PhD

Jean-Yves Blay, MD/PhD

Axel Le Cesne, MD/PhD

The BCB SARCOMES database is a clinical and biological national database dedicated to sarcoma that contains 3 main databases with specific aims: the first is the pathology database (French expert network dedicated to the management of bone sarcomas \[RESOS\] / French expert network dedicated to the pathology of sarcomas \[RREPS\]), dedicated to systematic review of mesenchymal tumor diagnostics nationwide; the second is clinical (RESOS / French expert clinical network for sarcomas \[NETSARC\]), collecting multidisciplinary tumor boards (MDTB) data of patients nationwide, and the third (CONTICABASE / BONE / GIST) is dedicated to collecting patients longitudinal/follow up data, with a focus on treatments of every events, and a catalogue of associated samples.

Primary objectives of BCB-SARCOMES are the following: description of the patterns of care and treatment outcomes, assessment of the prognostic factors of patients' outcomes.

With the financial support of the French National Cancer Institute \[Institut National du cancer \[INCa\]).

National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group

The "BCB-sarcomes" Database: the Database of the French Sarcoma Group Dedicated to the Collection of Clinical and Biological Data for All Sarcomas

Time from the systemic treatment onset to the next treatment or death due to any cause, whichever comes first. When neither death nor new systemic therapy is observed, TNT is censored at the date of last patient contact.

Interval between diagnosis and the time of death. When death is not observed, OS is censored at the date of last patient contact.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
METASARC: Patterns of Care and Outcomes in METAstatic Soft Tissue SARComa	NCT03977818	Sarcoma Metastases Chemotherapy		18 Years -	Institut Bergonié
National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group	NCT03978039	Sarcoma	Chemotherapy Immunotherapeut... target treatmen... Surgery Radiotherapy	-	Institut Bergonié
National Clinical and Biological Sarcoma Database : An Initiative of the French Sarcoma Group	NCT03978039	Sarcoma	Chemotherapy Immunotherapeut... target treatmen... Surgery Radiotherapy	-	Institut Bergonié

Spots Global Cancer Trial Database for patterns of care